dedup-isc-ft-v107-score
float64 0.3
1
| uid
stringlengths 32
32
| text
stringlengths 1
17.9k
| paper_id
stringlengths 8
11
| original_image_filename
stringlengths 7
69
|
|---|---|---|---|---|
0.474502 | b6a4d6f634d6484f923537a275b1bd9d | Curve of the training results. (a) Training and validation of various loss curves; (b) Change curve of evaluation index. | PMC10216973 | entropy-25-00808-g014a.jpg |
0.450486 | 2514eab4ac534907aa58da409a546721 | (a) P–R curves; (b) F1 score curves; the blue line is the average of all classes. | PMC10216973 | entropy-25-00808-g015.jpg |
0.391004 | 946d6f0599e54b12a0668fe41337b39d | Detection results of different models. GT is the label for the target. Rows 2–5 show the test results of the SSD, Yolov3-tiny, Yolov5s, Yolov5, Yolov7-tiny, and MSIA-Net models, respectively. | PMC10216973 | entropy-25-00808-g016a.jpg |
0.407755 | 4025be95a5174f239fef0ac2b2fac827 | Comparison of test results of PAN and LIR-FPN structures. | PMC10216973 | entropy-25-00808-g017.jpg |
0.457656 | ae188f0e02e24b1e9228d2e376039238 | NIF enhances neural cell viability following injury. Tissue sections representing controls, INJ alone, or treatment with NIF. (A) Immunofluorescent images of viable cells (calcein-AM (Cal) green, white arrow heads) and nuclei of dead cells (ethidium homodimer-AM (EthD-1) red, asterisks). (B) Quantification of cell viability per cubic micrometer. Data are presented as the mean ± SEM of 8 to 10 slices/animal with 6 animals per experimental group. (***) indicates p < 0.001. | PMC10217115 | cimb-45-00252-g001.jpg |
0.398114 | 051b9b15a93141e8a3675d7e234529a5 | NIF reduces apoptosis following brain tissue injury. Tissue sections representing controls, INJ alone, or treatment with NIF. (A) Immunofluorescent images showing apoptotic cells (green, white arrow heads). Scale bar: 20 µm. (B) Assessment of apoptosis. Data are presented as the mean ± SEM of 8 to 10 slices/animal with 6 animals per experimental group. (***) indicates p < 0.001. | PMC10217115 | cimb-45-00252-g002.jpg |
0.377567 | 2b28d2ed86a249f2934d0d15b2ea0089 | NIF reduces MBP+ OL loss following brain tissue injury. Tissues representing controls, INJ alone, or treatment with NIF. (A) Immunofluorescent images of MBP+ OLs (white arrowheads) and condensed and fragmented nuclei (white asterisks). Scale bar: 20 µm. (B) Measurement of MBP+ OLs. (C) Quantification of apoptotic nuclei among MBP+ OLs. Data shown are the mean ± SEM of 8 to 10 slices/animal with 6 animals per group. * indicates p < 0.05; ** indicates p < 0.01, and *** indicates p < 0.001. | PMC10217115 | cimb-45-00252-g003.jpg |
0.456719 | f8d8b8d18ac045158f23425b8c908c67 | NIF reduces NG2+ OPC loss following insult. Tissue sections representing controls, INJ alone, or treatment with NIF. (A) Immunofluorescent images of NG2+ OPCs (white arrowheads) and pyknotic nuclei (white asterisks). Scale bar: 20 µm. (B) Measurement of NG2+ OPCs. (C) Quantification of apoptosis. Data are shown as the mean ± SEM of 8 to 10 slices/animal with 6 animals per each experimental group. * indicates p < 0.05 and *** indicates p < 0.001. | PMC10217115 | cimb-45-00252-g004.jpg |
0.39698 | 7d9c66ec915a42a78f768f53b2659077 | NIF preserves mitotic behavior of NG2+ OPCs following insult. Tissue sections representing controls, INJ alone, or treatment with NIF. Immunofluorescence images of (A) dividing (BrdU+) cells (white asterisks) and (C) proliferating NG2+ OPCs (white arrowheads). Scale bar: 20 µm. (B) Measurement of BrdU+ cells. (D) Measurement of proliferating NG2+ OPCs. Data are presented as the mean ± SEM of 8 to 10 slices/animal with 6 animals per each experimental group. * indicates p < 0.05; *** indicates p < 0.001. | PMC10217115 | cimb-45-00252-g005.jpg |
0.384405 | 6155fe30f28144fdbeb30dd8b302c32e | Flank wear rate vs. cutting length. | PMC10217320 | entropy-25-00771-g001.jpg |
0.534549 | b80130c6952e498495fa58eb61596559 | Wear intensity of the carbon current collecting material over time. | PMC10217320 | entropy-25-00771-g002.jpg |
0.391157 | 97102cf47497454ca26ecee97e05ad6c | Wear intensity of the antifriction material and steel over time. | PMC10217320 | entropy-25-00771-g003.jpg |
0.461242 | 54adee31472c41349c7e7dcac2cbaccb | Surface of aluminum antifriction alloy prior to friction: (a)—image in secondary electrons; (b)—magnesium distribution map. | PMC10217320 | entropy-25-00771-g004.jpg |
0.417537 | f645c5be464f4ba68dd4f60ac4cbbe08 | The friction surface of aluminum antifriction alloy: (a)—image in secondary electrons; (b)—magnesium distribution map. | PMC10217320 | entropy-25-00771-g005.jpg |
0.468389 | 4a33535401f04cbaa2d7454206a23e0d | Concentration profile of magnesium in a plane perpendicular to the friction surface at a length of 50 μm. The friction surface is on the right. | PMC10217320 | entropy-25-00771-g006.jpg |
0.390677 | 64da294e48a64e5483de1680757ec7c7 | Breast cancer diagnosed in 2020; report by WHO. | PMC10217686 | diagnostics-13-01688-g001.jpg |
0.457949 | 903676c1175c4bb883769637aa511f74 | Proposed EBCSP framework working view. | PMC10217686 | diagnostics-13-01688-g002.jpg |
0.409812 | 6544f6fec37e4abea2ac98bfe16031cc | DNN architecture designed for CVN data. | PMC10217686 | diagnostics-13-01688-g003.jpg |
0.424165 | f6a9eda2c11c47d39f5c5f16988696f0 | CNN architecture designed for Clinical data. | PMC10217686 | diagnostics-13-01688-g004.jpg |
0.405836 | 2424318703014bbb86192a1977a09fd0 | RNN-LSTM architecture designed for Gene Expression data. | PMC10217686 | diagnostics-13-01688-g005.jpg |
0.435202 | a3a7a094ca6449b8b02b4f0c8f6e7264 | ROC curve for the EBCSP model feature extraction for prognosis prediction. | PMC10217686 | diagnostics-13-01688-g006.jpg |
0.424242 | 96ba1df0b96240949a3c596b9d1f0773 | AUC and ACC comparison between data modalities. | PMC10217686 | diagnostics-13-01688-g007.jpg |
0.427509 | 1614e611c3a441e5952808e6abe4b7d5 | Result evaluation of EBCSP model with existing benchmarks. | PMC10217686 | diagnostics-13-01688-g008.jpg |
0.435921 | 6499dc931f904137bf53a75d77addcef | Flow diagram showing the recruitment process and study completion by participants. | PMC10217717 | children-10-00802-g001.jpg |
0.434131 | d65ec4b51e8c4a2e80ec4fc56ad41543 | Paired box plots depicting changes in PD15 before and after treatment for all patients of the cohort (A); and after exclusion of patients with a negative MDP challenge at both evaluation time points (B). | PMC10217717 | children-10-00802-g002.jpg |
0.488933 | 5409eb3289bf4922b67574d4c7472ca4 | Box plots depicting the distribution of the PD15 value among the clinical groups. The PD15 at baseline tended to be lower in the presence of nocturnal asthma symptoms that were either accompanied or not by the presence of exercise-induced asthma. | PMC10217717 | children-10-00802-g003.jpg |
0.387636 | 978e066417b7471d9b2dfab2473aa9f0 | Box plots depicting the association between the PD15 value and the existence of nocturnal asthma symptoms (A) or exercise-induced asthma (B). The PD15 was significantly lower when patients reported asthma-related symptoms during nocturnal sleep (p = 0.03), whereas it was not affected by the presence of exercise-induced asthma (p = 0.73). | PMC10217717 | children-10-00802-g004.jpg |
0.39928 | e7bbc684fd8145878e8b32540d8988b5 | Students’ interest in birds (Q14) regarding the factors studied: (a) RR, (b) TS, (c) PES, (d) PV and (e) EL. Asterisk stands for significant differences (p < 0.05) and dashed lines represent the mean. | PMC10218049 | ijerph-20-05769-g001.jpg |
0.426014 | 14c59f1e8d8c44499a06e813226afb4f | Students’ bird species identification scores (Q17) regarding the factors studied: (a) RR, (b) TS, (c) PES, (d) PV and (e) EL. The asterisk stands for significant differences (p < 0.05) and dashed lines represent the mean. | PMC10218049 | ijerph-20-05769-g002.jpg |
0.421878 | f528ec490eec443c9e3fe6ddacefb3c1 | Students’ correct and halfway-correct identification percentages for ten bird species present in the UBR. | PMC10218049 | ijerph-20-05769-g003.jpg |
0.414712 | 5b13e11b28a449ac85686ed6d797ee4d | Boxplot and regression line for bird identification score and the time passed from conducting the EE program at UBC and fulfilling the bird identification task in the questionnaire (Retention Time, n = 182). | PMC10218049 | ijerph-20-05769-g004.jpg |
0.478984 | 0200f9090c9b4585b2f9b90df715a6ee | Students’ responses to Likert-type questions regarding conservational attitudes towards the UBR (Q18–Q22). | PMC10218049 | ijerph-20-05769-g005.jpg |
0.421937 | dbded80d8e0c4c558f83a4e1653dc69f | Chemical structures of some natural-based chalcones having anti-SARS-CoV activity. | PMC10218655 | ijms-24-08789-g001.jpg |
0.516899 | 84d7ec16285645d29a268b278c58c9df | The ROC curve (A-1) 3CLpro and (A-2) PLpro benchmarking datasets. The area under the curve is 0.84 and 0.849 for 3CLpro and PLpro, respectively. (B) Docking score (kcal/mol) distribution of the 757 chalcone-based compound library over the 12 host-based molecular targets consisted of CDK9/cyclinT1 (3BLR), ERK2 (3SA0), p38 MAPK (4EH3), RBD2 (4J1P), HDAC2 (4LXZ), CK2 alpha’ (5M4U), Cathepsin L (5MQY), DHODH (5ZF7), Sigma-1 receptor (6DK1), CDK1 (6GU2), CDK2/CyclinA (6GUB), and RBD4 (6HOV) and the two viral targets 3CLpro (6M2N) and PLpro (7JN2). The intersecting line in each cluster represents the average docking score in each target. | PMC10218655 | ijms-24-08789-g002.jpg |
0.431664 | f25f2ca921c74e8fa1fffe3110649c41 | Chemical structure of some of the famous SARS-CoV-2 inhibitors hirsutenone, baicalein, and GRL0617 and their experimentally reported potencies, and also newly reported SARS-CoV-2 3CLpro fragment inhibitors A and B. The most active compounds CHA-12, CHA-37, CHA-297, CHA-378, and CHA-384 were selected as the promising chalcone-based structures for the inhibition of SARS-CoV-2 and identified by our preliminary in silico screening protocol. | PMC10218655 | ijms-24-08789-g003.jpg |
0.413843 | 47695333f6ef4fcbab7ab607f2eeb126 | (A,B) RMSD plots for Cα variations during the MD simulation time 50 ns for the 3CLpro and PLpro complexes, respectively. (C,D) RMSF plots for Cα variations during the MD simulation time of 50 ns for the 3CLpro and PLpro complexes, respectively. (E,F) 2D projection of the first and second eigenvectors for the 3CLpro and PLpro complexes, respectively. For the 3CLpro complexes: black: baicalin, red: CHA-12, green: CHA-384, blue: CHA-37, brown: CHA-297, cyan: CHA-378, magenta: hirsutenone, violet: compound A, and orange: compound B. For the PLpro complexes: black: co-crystal ligand, red: GRL0617, green: CHA-12, blue: CHA-37, brown: CHA-378, and cyan: hirsutenone. | PMC10218655 | ijms-24-08789-g004.jpg |
0.444775 | 963ebfe5f30645ae823957611fde6fc3 | Binding free energy (ΔGb) of compounds calculated by the MM/GBSA (blue) and MM/PBSA (red) methods in the active sites of the 3CLpro (A) and PLpro (B). | PMC10218655 | ijms-24-08789-g005.jpg |
0.445845 | cb8b089303cd489f940bb9bda31afeea | 2D and 3D interactions of CHA-12 in the active site of the SARS-CoV-2 3CLpro and PLpro enzymes. | PMC10218655 | ijms-24-08789-g006.jpg |
0.429506 | 242daf0757244591ab4f6dc30092f363 | Interactions of CHA-297 and CHA-378 in the active site of the SARS-CoV-2 3CLpro and PLpro enzymes. | PMC10218655 | ijms-24-08789-g007.jpg |
0.408661 | dce1673b1e154c788f5c53dc7ed11948 | 2D and 3D interactions of (A) GRL0617 (as a standard SARS-CoV-2 PLpro inhibitor) and (B) CHA-37 in the active site of the SARS-CoV-2 PLpro enzyme. | PMC10218655 | ijms-24-08789-g008.jpg |
0.380085 | 01f21483502746efbd69909bd4e742cb | Energy components of the compounds calculated by the MM/GBSA and MM/PBSA in the 3CLpro. Enthalpic components of baicalein in MM/GBSA (A) and MM/PBSA (B) analysis and its binding free energy (ΔGb) decomposed to the enthalpy (ΔH) and entropy (-TΔS) terms in the MM/GBSA (C) and MM/PBSA (D) calculations. Correspondingly, enthalpic components and binding free energy (ΔGb) terms for CHA-12 in the MM/GBSA and MM/PBSA calculations are respectively illustrated in (E–H). Enthalpic components and binding free energy (ΔGb) terms for CHA-384 in the MM/GBSA and MM/PBSA calculations are respectively illustrated in (I–L). Enthalpic components and binding free energy (ΔGb) terms for CHA-37 in the MM/GBSA and MM/PBSA calculations are respectively illustrated in (M–P). Enthalpic components and binding free energy (ΔGb) terms for hirsutenone in the MM/GBSA and MM/PBSA calculations are respectively illustrated in (Q–T). Enthalpic components and binding free energy (ΔGb) terms for CHA-378 in the MM/GBSA and MM/PBSA calculations are respectively illustrated in (U–X). VDWAALS: van der Waals energy, EEL: electrostatic energy, EGB: polar solvation energy calculated by the MM/GBSA, ESURF: non-polar solvation energy calculated by the MM/GBSA, EPB: polar solvation energy calculated by the MM/PBSA, ENPOLAR: non-polar solvation energy calculated by the MM/PBSA. | PMC10218655 | ijms-24-08789-g009.jpg |
0.399921 | 148f44913a304c53bb4f894d4cd0347a | Energy components of the compounds calculated by the MM/GBSA and MM/PBSA in the PLpro. Energy components of GRL0617 in the MM/GBSA (A) and MM/PBSA (B) analysis and its binding free energy (ΔGb) decomposed to the enthalpy (ΔH) and entropy (-TΔS) terms in the MM/GBSA (C) and MM/PBSA (D) calculations. Correspondingly, energy components and binding free energy (ΔGb) terms for CHA-12 in the MM/GBSA and the MM/PBSA calculations are respectively illustrated in (E–H). Energy components and binding free energy (ΔGb) terms for CHA-37 in the MM/GBSA and MM/PBSA calculations are respectively illustrated in (I–L). Energy components and binding free energy (ΔGb) terms for hirsutenone in the MM/GBSA and MM/PBSA calculations are respectively illustrated in (M–P). VDWAALS: van der Waals energy, EEL: electrostatic energy, EGB: polar solvation energy calculated by the MM/GBSA, ESURF: non-polar solvation energy calculated by the MM/GBSA, EPB: polar solvation energy calculated by the MM/PBSA, ENPOLAR: non-polar solvation energy calculated by the MM/PBSA. | PMC10218655 | ijms-24-08789-g010.jpg |
0.41727 | 7f44060b2d8b48418ac1d2c2fca36bbc | Structural similarity of CHA-12, losartan, and candesartan cilexetil due to the existence of a phenyltetrazole moiety. | PMC10218655 | ijms-24-08789-g011.jpg |
0.367159 | 128371ad8d4c421ab1cdbf0de5de627b | A summary of the remarkable potentials of CHA-12 to combat SARS-CoV-2 infection as well as to reduce the pulmonary complications of COVID-19. The excellent relaxant effects of CHA-12 on pulmonary smooth muscle through antagonistic activity on CysLT1 (proven in vivo and in vitro), along with the prediction of remarkable effects on all host-based and SARS-CoV-2 3CLpro and PLpro targets, promise the discovery of a unique compound with high potential for the treatment of COVID-19. | PMC10218655 | ijms-24-08789-g012.jpg |
0.400648 | a761dbe9078048458aa99ac99cf3482d | (A) The chemical structure of CHA-297, CHA-378 and its structural similarity with compound A and hirsutenone. (B) Structures of compounds C
D and E. | PMC10218655 | ijms-24-08789-g013.jpg |
0.484217 | a54bd24a747f49ea8e028da665f0a825 | Structural similarity of the identified selective-3CLpro ligands CHA-233, CHA-236, CHA-383, CHA-384, CHA-392, and CHA-397, the recently reported biaryl urea compounds B and E, and their isosteric amide-analogue compounds F and G as special fragments introduced for the design and development of 3CLpro-inhibitors. | PMC10218655 | ijms-24-08789-g014.jpg |
0.49761 | 66cf3bf2648545269904405fe421dc91 | (A) Compound B in the active site of the 3CLpro. (B) Establishment of the two hydrogen bonds formed in the active site of the SARS-CoV-2 3CLpro by the ureide-chalcone hybrid structures CHA-233, CHA-236, CHA-383, CHA-384, CHA-392, and CHA-397 and the carbonyl group of Arg188. | PMC10218655 | ijms-24-08789-g015.jpg |
0.416156 | 07f3bc61f8114daa8e9e12983cbc29a9 | Spatial orientation and establishment of the two hydrogen bonds by the ureide-chalcone hybrid structures CHA-233, CHA-236, CHA-383, CHA-384, CHA-392, and CHA-397 with the carbonyl group of Arg188 at the active site of the SARS-CoV-2 3CLpro. | PMC10218655 | ijms-24-08789-g016.jpg |
0.42687 | 16daaaad131f4569a189ae6a572b8983 | (A) Structural similarity of the chalcone and the chalcone amide scaffolds, and GRL0617 as a well-known inhibitor of SARS-CoV PLpro. (B) The structure of the predicted selective ligands CHA-11, CHA-37, and CHA-44 toward SARS-CoV-2 PLpro. (C) Structure of the fluorophenyl containing chalcones CHA-177 and CHA-7 and the previously reported compounds L and M. Asterisk in the structure of chalcone indicates the location of the bioisosteric replacement. | PMC10218655 | ijms-24-08789-g017.jpg |
0.436631 | 24c7c523fd71449d8c7e15287d6edd44 | Chemical structures of CHA-37 and some potent SARS-CoV 3CLpro inhibitors containing benzotriazole scaffold. | PMC10218655 | ijms-24-08789-g018.jpg |
0.513879 | 4b0f716e9b56459a9e2e56e2d6861169 | 2D and 3D interactions of compound J as a highly potent reported SARS-CoV-2 3CLpro inhibitor and CHA-37 in the active site of the 3CLpro enzyme. | PMC10218655 | ijms-24-08789-g019.jpg |
0.477718 | 89bb4f444be8497088b794d16aa5756d | Calcium ion (Ca2+) channels in Saccharomyces cerevisiae. (A) Channel localization. (B–D) Predicted topologies of Ca2+ channels Cch1, Mid1, and Yvc1; the plus sign indicates the positively charged amino acids; solid circle indicates the cysteine (Cys) residues (Cch1, Yvc1) or Cys-rich regions (Mid1); hollow circle indicates the EF-hand-like motif of helix–loop–helix structure; solid triangle indicates the CKII phosphorylation motif; hollow triangle indicates the sheet–turn–sheet structure; solid square indicates the hydrophobic patch between the amino acid residues 509 and 518; hollow square indicates the negatively charged cluster 573DDDD576. | PMC10218840 | jof-09-00524-g001.jpg |
0.421178 | 4ef516d2d9bd446dbefe3e7693bab012 | Structure of the α1 subunit in Cav1.1 [25,26]. (A) Overall structure of α1 subunit; CTD, C- terminal domain; red spheres indicate the tentatively assigned calcium ions (Ca2+) in the selectivity filter vestibule. (B) Structural elements of the selectivity filter. (C) Four-fold pseudo-symmetry of the pore domain; loops between S5 and P1 helices and between P2 and S6 helices are shown as L5 and L6 loops, respectively. (D) Structures of the four voltage-sensing domains (VSDs). Gating charges on helix S4 and the occluding phenylalanine residue on S2 are shown as sticks. | PMC10218840 | jof-09-00524-g002.jpg |
0.423047 | e7a1ad2a084d436b910c984bc894d143 | Applications of calcium ion (Ca2+) channels in Saccharomyces cerevisiae. SMCs, smooth muscle cells; CMCs, cardiac muscle cells; S. C., Saccharomyces cerevisiae; A. N., Aspergillus niger; MSCs, mesenchymal stem cells. | PMC10218840 | jof-09-00524-g003.jpg |
0.452965 | 4c4d544caa7d4348b5bb0698c2fe7c98 | Maximum likelihood tree based on ITS (the nuc rDNA internal transcribed spacer region ITS1-5.8S-ITS2) sequences of specimens of Cystolepiota and related genera. Bootstrap values of ML ≥ 50%, and BI ≥ 0.90 are indicated above the branches (ML/BI). Specimens sequenced within this study are in bold. Type collections are marked with an asterisk. The clades representing the C. seminuda complex are highlighted by grey boxes. C. = Cystolepiota; E. = Echinoderma; M. = Melanophyllum; P. = Pulverolepiota. E. flavidoasperum, E. asperum and E. hystrix are used as outgroup. | PMC10218902 | jof-09-00537-g001.jpg |
0.461526 | f31c7c5eb3b149189dee8d77dfca2c28 | Maximum likelihood tree inferred from a combined data set of ITS, LSU (the D1–D2 domains of nuc 28S rDNA), rpb2 (the most variable region of the second-largest subunit of RNA polymerase II), and tef1 (a portion of the translation–elongation factor 1-α) sequences of specimens of Cystolepiota and related genera. Bootstrap values of ML ≥ 50%, and BI ≥ 0.90 are indicated above the branches (ML/BI). Specimens sequenced within this study are in bold. Type collections are marked with an asterisk. The clade standing for C. seminuda complex is highlighted by a grey box. C. = Cystolepiota; Co. = Coprinus; E. = Echinoderma; L. = Lepiota; M. = Melanophyllum; P. = Pulverolepiota; S. = Smithiomyces. Co. comatus and Co. sterquilinus are used as outgroup. | PMC10218902 | jof-09-00537-g002.jpg |
0.457988 | 819f489869ae4c7488f4ed6d14811553 | Basidiomata of Cystolepiota and Pulverolepiota species. (A–C). C. pseudoseminuda. (A). KUN-HKAS 92275(Holotype). (B,C). KUN-HKAS 73969. (D–F). C. seminuda. (D). KUN-HKAS 106008. (E). KUN-HKAS 106016. (F). KUN-HKAS 54211. (G,H). P. oliveirae. KUN-HKAS 124759. (I). C. pyramidosquamulosa. KUN-HKAS 53985 (Holotype). Bars = 1 cm. | PMC10218902 | jof-09-00537-g003.jpg |
0.524882 | 637dd2bf1beb4fefb00c5940d0fa3700 | Basidiospores of Cystolepiota and Pulverolepiota species under SEM. (A,B). C. aff. pseudoseminuda 1. (A). GLM-F116532. (B). GLM-F061278. (C,D). C. pseudoseminuda. (C). KUN-HKAS 92275 (Holotype). (D). KUN-HKAS 73969. (E–G). C. seminuda. (E). KUN-HKAS 106016. (F). GLM-F125824 (Neotype). (G). GLM-F042189. (H,I). Lepiota sororia. L0054151 (Holotype). (J,K). P. oliveirae. KUN-HKAS 124759. (L). C. pyramidosquamulosa. KUN-HKAS 53985 (Holotype). Bars = 1 μm. | PMC10218902 | jof-09-00537-g004.jpg |
0.545432 | 1a25532a6fe54fffb15570cd36fde0e0 | Microscopic features of Cystolepiota pseudoseminuda (Holotype, KUN-HKAS 92275). (A): Basidiospores. (B): Basidia. (C): Squamule cells. Bars: (A) = 5 μm; (B,C) = 10 μm. | PMC10218902 | jof-09-00537-g005.jpg |
0.397713 | dc7c142e029a4f58910a372e92549759 | The scatter diagram of spore lengths and spore length–width ratios of species in the Cystolepiota seminuda complex. | PMC10218902 | jof-09-00537-g006.jpg |
0.489434 | a2d374150d084e659e7cd8273445acc3 | Microscopic features of Cystolepiota pyramidosquamulosa (Holotype KUN-HKAS 53985). (A): Basidiospores. (B): Basidia. (C): Squamule cells. Bars: (A) = 5 μm; (B,C) = 10 μm. | PMC10218902 | jof-09-00537-g007.jpg |
0.520093 | 096359bfeacf45b58597b6f2c253399b | Microscopic features of Cystolepiota seminuda. (A): Basidiospores. (B): Basidia. (C): Squamule cells. (A,B) from GLM-F109912, (C) from KUN-HKAS 106016. Bars: (A) = 5 μm; (B,C) = 10 μm. | PMC10218902 | jof-09-00537-g008.jpg |
0.509971 | a0ba1d59ddfe43eeb301935330b4c6c1 | Microscopic features of Cystolepiota oliveirae (KUN-HKAS 124759). (A): Basidiospores. (B): Basidia. (C): Tightly arranged squamule cells. (D): loosely arranged squamule cells. Bars: (A) = 5 μm; (B) = 10 μm. (C) = 20 μm. (D) = 20 μm. | PMC10218902 | jof-09-00537-g009.jpg |
0.467901 | 8e5677ac5c3d451b92eac965769e9e5b | Study assessments conducted on the single day study visit. Abbreviations: MRI = magnetic resonance imaging, GLS = global longitudinal strain, MBF = myocardial blood flow, LV = Left ventricular, ECV = extracellular volume, CPET = cardiopulmonary exercise testing. | PMC10219263 | jcdd-10-00191-g001.jpg |
0.426724 | 0478c63922cf4d009f497fb65494125c | Difference in the mean value between groups for important exercise and cardiovascular measures for diabetic cardiomyopathy (T2D-remission—active-T2D). | PMC10219263 | jcdd-10-00191-g002.jpg |
0.437761 | f601639eaa714c349727ad574a6cae7a | Diagram of finishing chemistry approaches to fabric treatment. The schematic emphasizes and details the differences applying the formulations to the fabric through a spray technology versus a pad and dry. In the case of Pad–Spray–Dry optimal wet pickup of the calcium chloride was realized by padding the fabric prior to the spraying step. | PMC10219473 | jfb-14-00255-g001.jpg |
0.440502 | 851b9f6a4b694adfb5b499b4a7e24425 | The time to clot (k) formation TEG data of separate TACGauze (TGz) swatches treated with the following formulations and controls presented in this graph consist of: (l.-r.) TACGauze untreated (TGz Ctl); 0.5% Pectin + 2% CaCl2 + 5% NaY (0.5P2Ca5NaY); 0.25% Pectin + 10% NaY (0.25P10NaY); 1% CaCl2: 2% Pectin + 10% NaY sprayed (1C2P10NaY(S)); 0.5% Pectin + 10% NaY (0.5P10NaY); and 1% CaCl2 + 10% NaY (1Ca10NaY). Error bars represent the standard deviation of duplicate determinations. | PMC10219473 | jfb-14-00255-g002.jpg |
0.460188 | 40f421e6dd4b49d3a89747b4371ebc25 | Scanning Electron Microscopy (SEM) micrographs taken of TGz treated fabric swatches with (left-right, top to bottom) (a) 1% CaCl2 (pad) + 2% pectin + 10% NaY zeolite (spray); (b) 1% CaCl2 + 10% NaY zeolite; (c) 0.5% pectin + 10% NaY zeolite(pad); and (d) 0.5% pectin + 10% NH4Y zeolite. Micrographs (a–c) are shown at 1000× magnification and (d) at 2000× magnification. | PMC10219473 | jfb-14-00255-g003.jpg |
0.389657 | 71cbdec56ef342d795e06c9de07e224a | (a) FTIR spectra of TACGauze (TGz) (solid blue line) and NaY zeolite powder (gray dotted line). Spectra are presented normalized to their highest peak and as the average of four examination spots. (b) FTIR spectra of TGz fabrics treated with NaY zeolite, pectin, and CaCl2. An untreated TGz (control) is also shown. Spectra are presented normalized to 1050 cm−1 and as the average of four examination spots. A relative increase in the intensity of the 998 cm−1 peak is observed for the gauze fabrics treated with increasing NaY zeolite. | PMC10219473 | jfb-14-00255-g004.jpg |
0.395032 | 738ccaead10d4dfa9ae1447d258d3faa | (a) Graphed time to fibrin (R) and clot (K) formation TEG data of TACGauze (TGz) treated, 0.5%Pectin + 2%CaCl2 + 5%NaY, before (orange) and after rinsing (green) with add-ons of 40.4% and 20.6%, respectively. Error bars represent the standard deviation of duplicate determinations. (b) FTIR spectra of a TGz fabric treated with NaY zeolite, pectin, and CaCl2, before and after rinsing. An untreated TGz (control) is also shown. Spectra are presented normalized to 1050 cm−1 and as the average of four examination spots. | PMC10219473 | jfb-14-00255-g005.jpg |
0.441921 | 54874d675b6b4e168fac690afde1c596 | Formulary films of (a) sodium Y(NaY) or (b) ammonium Y (NH4Y)zeolite containing pectin and/or calcium compared to its respective powder. | PMC10219473 | jfb-14-00255-g006.jpg |
0.491943 | 9ee5fda0cea94c55b11c5f3aaf7a1429 | Consort flow diagram | PMC10220176 | JOACP-38-121-g001.jpg |
0.400934 | 496edcd6b4084bb2afadaa14658ddd41 | Aerosol box | PMC10220176 | JOACP-38-121-g002.jpg |
0.420293 | bd15448a610b47d4bf6b196caaf73a67 | Process and criteria for selecting participants. | PMC10220856 | life-13-01197-g001.jpg |
0.523891 | 1efc2ae5a4a143af9f6f94c95279800a | Kaplan–Meier curve for estimating time until relapse/recurrence between the continuous pharmacological treatment and early discontinued pharmacological treatment groups, compared by log-rank test. | PMC10220856 | life-13-01197-g002.jpg |
0.464517 | f4900f9253e84204baa9e4babd869443 | Flow chart of the parameter estimation [24]. | PMC10220989 | sensors-23-04760-g001.jpg |
0.387569 | dd690b2fb07d49e6827e6593d332110a | Estimation accuracy analysis of k, µ parameter estimation methods based on Monte Carlo method generated k-µ channel data; (a) Comparison and error of theoretical PDF and estimated PDF curves at k = 2, µ = 1; (b) Comparison and error of theoretical PDF and estimated PDF curves at k = 4, µ = 1; (c) Comparison and error of theoretical PDF and estimated PDF curves at k = 4, µ = 2; (d) Comparison and error of theoretical PDF and estimated PDF curves at k = 6, µ = 2. | PMC10220989 | sensors-23-04760-g002a.jpg |
0.479514 | 78ba7dc8e6f14cbcb232056836603ea5 | Estimation accuracy analysis of k, µ parameter estimation algorithm based on Monte Carlo method generated k-µ channel data; (a) Comparison the error of theoretical PDF and estimated PDF curves at k = 0, µ = 1; (b) Comparison the error of theoretical PDF and estimated PDF curves at k = 0, µ = 1.5; (c) Comparison the error of theoretical PDF and estimated PDF curves at k = 0, µ = 2. | PMC10220989 | sensors-23-04760-g003.jpg |
0.447483 | 3c8c8df0940440819b6bd4a566290607 | Impact analysis of estimator performance based on different SNR conditions; (a) Error comparison of theoretical and estimated PDF curves at k = 3.5, μ = 1.5, SNR = 30 dB; (b) Error comparison of theoretical and estimated PDF curves at k = 3.5, μ = 1.5, SNR = 25 dB; (c) Error comparison of theoretical and estimated PDF curves at k = 3.5, μ = 1.5, SNR = 20 dB; (d) Error comparison of theoretical and estimated PDF curves at k = 3.5, μ = 1.5, SNR = 15 dB. | PMC10220989 | sensors-23-04760-g004a.jpg |
0.459403 | 0416aea0b5b44791acba0a661af817b3 | Impact analysis of estimator performance based on different SNR conditions: (a) The power delay spectrum and PDF values of parameters k and µ when N = 8500; (b) The power delay spectrum and PDF values of parameters k and µ when N = 8000; (c) The power delay spectrum and PDF values of parameters k and µ when N = 5000; (d) The power delay spectrum and PDF values of parameters k and µ when N = 2600; (e) The power delay spectrum and PDF values of parameters k and µ when N = 1000. | PMC10220989 | sensors-23-04760-g005a.jpg |
0.485058 | ea27ebc1162947feaa9d8aef5d226e72 | Correlation between total BMD (g/cm2) and height measured by technician (cm). | PMC10221187 | medicina-59-00862-g001.jpg |
0.362856 | bac8af377bd14c9ba3b0e63eb20f58c1 | Sankey plots of overall gastrointestinal symptoms at (from left to right) T1 (8.4 months after hospital discharge) vs. T2 (13.2 months after hospital discharge) and vs. T3 (18.3 months after hospital discharge). The X axis represents the time points while the Y axis represents the percentage of individuals suffering (or not suffering) from gastrointestinal symptomatology. The darker vertical bars represent the percentage of individuals who, at that particular time point, were negative or positive for overall gastrointestinal symptomatology. | PMC10221203 | viruses-15-01134-g001.jpg |
0.434062 | bbaa1734e042491cb5269fac1625ba0d | Sankey plots of diarrhea at (from left to right) T0 (hospital admission, COVID-19 onset) vs. T1 (8.4 months after hospital discharge), vs. T2 (13.2 months after hospital discharge), and vs. T3 (18.3 months after hospital discharge). The X axis represents the time points while the Y axis represents the percentage of individuals suffering (or not suffering) from diarrhea. The darker vertical bars represent the percentage of individuals who, at that particular time point, are negative or positive for diarrhea. | PMC10221203 | viruses-15-01134-g002.jpg |
0.418879 | 1271e0f4a2bb4f06a46eddafd228763a | Exponential recovery curve of self-reported diarrhea (in orange) and overall gastrointestinal (in light blue) symptoms. Opacity approximately indicates the sample size at that follow-up time. Asterisks represent the mean values at the T0, T1, T2, and T3 follow-up points. | PMC10221203 | viruses-15-01134-g003.jpg |
0.427421 | 6925810a3f304de29fc1a271f7901be1 | Life cycle of Ixodiphagus spp. | PMC10221573 | pathogens-12-00676-g001.jpg |
0.442863 | 3ec5060c7bf34a63ab00337e82823a9e | Ixodiphagus sp. larva in a Rhipicephalus sanguineus s.l. tick (Scale bar = 200 μm). | PMC10221573 | pathogens-12-00676-g002.jpg |
0.535194 | 5053fbbaa8564b6682fca610bbad1d4c | (a) Extended BVD electric model of the QCM sensor, (b) half-bridge configuration for the virtual impedance analyzer. | PMC10221602 | sensors-23-04939-g001.jpg |
0.480491 | 784ece74502549d597b93f26c683ab59 | Simulation of the extended BVD model of the QCM sensor in air: (a) Bode plot, (b) Nyquist plot. | PMC10221602 | sensors-23-04939-g002.jpg |
0.496806 | 6a3c8042f78946aba8495e244b5e515e | Simulation of the extended BVD model of the QCM sensor in water: (a) Bode plot, (b) Nyquist plot. | PMC10221602 | sensors-23-04939-g003.jpg |
0.401129 | 3c512ab77d4e4f2490bedf50e321f88e | Wide scanning range virtual impedance analyzer: (a) experimental setup, (b) half-bridge shield. | PMC10221602 | sensors-23-04939-g004.jpg |
0.456394 | f9e5c196d3774de6963cb44dbb2e4fd4 | Bode plot of raw data for the QCM sensor in the air and the electrical parameters of the extended BVD model for the series resonance, respectively the first two spurious resonances. | PMC10221602 | sensors-23-04939-g005.jpg |
0.400953 | 4a153b641ac84602ae731f55df91c98a | Bode plot of raw data for the QCM sensor in the water and the electrical parameters of the extended BVD model for the series resonance, respectively the first two spurious resonances. | PMC10221602 | sensors-23-04939-g006.jpg |
0.410675 | 01b0c6f022874469a67aa2ff27fce504 | Bode plot of raw data for the QCM sensor in the 40% glycerin-water solution and the electrical parameters of the extended BVD model for the series resonance, respectively the first two spurious resonances. | PMC10221602 | sensors-23-04939-g007.jpg |
0.40415 | 63127b4bbb7f4ac9bbc3d5adb618879f | Bode plot of raw data for the QCM sensor in the 80% glycerin-water solution and the electrical parameters of the extended BVD model for the series resonance, respectively the first two spurious resonances. | PMC10221602 | sensors-23-04939-g008.jpg |
0.44074 | 9aec09d2733e4a03b04affe8eb0cf641 | QCM sensor: (a) evolution of series resistance and series resonance frequency shift in air, water, and glycerol-water solution; (b) evolution of Q-factor and D-factor in air, water, and glycerol-water solution. | PMC10221602 | sensors-23-04939-g009.jpg |
0.475858 | c985b408c0114ed196a897617f27cb77 | Procedural steps of the 3D surface scanning method: (a) Loupe magnification and precision airbrush gun; (b) Application of the anti-reflective coating spray on the surface of the NiTi instrument; (c) NiTi rotary instrument covered by the anti-reflective coating; (d) Scanbox of the 12 MP laboratory-based optical scanner; (e) Laboratory-based scanner head during the scanning procedure; (f) Instrument mounted in the object holder during the 360° scanning process; (g) Virtual 3D model of the scanned instrument showing its triangulated mesh. | PMC10222178 | materials-16-03636-g001.jpg |
0.402813 | 896f198942304df7a777d4af7a2d7929 | Qualitative and quantitative validations: (a) SEM image of each deformed instrument (on the left) was visually compared to the virtual 3D model created by the scanning procedure (in the center). On the right, it is possible to observe the polygonal mesh of each virtual model; (b–e) Sides of ProTaper Next X2 (b) and EdgeOne Fire Primary (d) cross-sections analyzed by SEM (b,d) and by the 3D surface scanning method (c,e) showing the similarity of results; (f–i) Distances were calculated in the virtual models regarding the measuring lines references from 18 mm and 19 mm (f,h) and from 18 mm and 22 mm (g,i) of ProTaper Next X2 and EdgeOne Fire Primary instruments, demonstrating they were similar to known lengths reported by the manufacturers. Representative image of the SEM calibration grid (j). | PMC10222178 | materials-16-03636-g002.jpg |
0.376292 | 7e02bf9abd874525a3584195cb038df7 | Measurement assessments conducted on a ProTaper Next X2 instrument: (a) D0 was set at the base of instrument’s tip; (b) A total of 17 cross-section levels were established from D0 to D16; (c) Multiple measurements were conducted of each level showed in (b). | PMC10222178 | materials-16-03636-g003.jpg |
0.411145 | 8c60800e23ba4fe3a0366712c63bd2e2 | Optical scanners vs. micro-CT: (a) The 5 MP scan created a model with rounded blades, no tip, and severe artificial surface irregularities. The surface appearance of the 3D model acquired by the micro-CT scanner showed better quality than the 5 MP resolution scanner, but the generated model had slightly flattened blades and artificial surface irregularities, while the highest quality model was created by the 12 MP optical scanner; (b) Cross-section of the Reciproc instrument reconstructed from a micro-CT scan in which irregularities can be observed in its external surface after the binarization process caused by the high density of the metal alloy. | PMC10222178 | materials-16-03636-g004.jpg |
0.486544 | 822055c494ab4221af9809a3e4e1fb0a | Research application: changes in the instrument’s morphology. (a) Superimposition of 2 STL volumes from the same NiTi instrument (Reciproc R25) created before and after preparation of 8 mesial root canals of mandibular molars showing permanent geometric deformation at the apical area; (b) Changes in the design of the apical area were mostly due to unwinding; (c) In most of the coronal part of the blade no relevant changes were noticed. The black line in (b,c) represents the contours of the instrument before preparation. | PMC10222178 | materials-16-03636-g005.jpg |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.